The therapeutic potential of interstate-filled stem cells in a variety of pediatric diseases

In recent years, stem cell treatment of childhood diseases has attracted worldwide attention, including children's hospitals, a large number of medical institutions and scientific research units are focused on stem cell treatment of pediatric diseases clinical research.
2012, Canada approved stem cell drugs specifically designed to treat childhood grafts against host disease.
, stem cell therapy for pediatric diseases is in full swing around the world.
because children's immune systems are not as strong as those of young people, they are vulnerable to viruses in the outside world.
, finding a better and safer way to treat childhood diseases is particularly important.
interstiture stem cell therapy represents a potentially revolutionary treatment that has been widely used in the treatment of a variety of pediatric diseases and has shown great therapeutic potential in clinical trials of pediatric lung, heart, orthopaedic, endocrine, neurological and hematological diseases.
Today, we bring you together to understand the therapeutic potential of interstate stem cells in a variety of pediatric diseases, and to help you learn more about the clinical progress of interstate stem cells in pediatric diseases.
interstate charge stem cells for the treatment of children's transplant anti-host disease interstate charge stem cells have been successfully used to treat transplant anti-host disease, the international market for transplant anti-host disease interstumin stem cell drugs, and the domestic also entered the clinical trial stage, some new drugs for this disease of interstumined stem cells have obtained clinical approval.
transplant anti-host disease is a clinically complex disease that affects the function of a variety of organs, including the skin, gastrointestinal tract, liver, kidneys, bones, joints, muscles and lungs.
traditional treatments include immunosuppressants such as high doses of steroid hormones and cyclosporine, but many patients do not respond to or rely on these treatments and have many adverse side effects.
treatment rate of anti-host diseases of steroid-resistant acute grafts in children is as high as 73%.
Clinic reports that a 9-year-old leukemia boy who developed a treatment-resistant IV-grade transplant anti-host disease after a bone marrow transplant received in vitro amplified interstummal stem cells from his mother, and that after injection therapy, his symptoms were relieved and showed no signs of heterogenous reactions, the most successful case of survival in such a serious disease.
addition, placental-sourced membrane substitial cells (DSCs) successfully treated acute gastrointestinal graft anti-host disease in children, according to a study in Pediatr Transplant.
in this study, a 1-year-old suffered life-threatening acute gastrointestinal graft anti-host disease after an allogeneic hematopoietic stem cell transplant and developed resistance to steroids and mycophenolic acid (MMF).
finally received placental source membrane substation cell therapy, the overall situation improved.
four weeks of observation, the child was in complete remission.
interstitiochargic stem cells to treat spinal muscular dystrophy spinal muscular dystrophy in children is a degenerative neurodegenerative disease, there is no clinically good treatment.
clinical study reported that three children with spinal muscular dystrophy were treated with allogeneic bone marrow-filled stem cells, significantly improving muscle strength, facial expressions, ventilator-free breathing and speech skills.
that the mechanism by which interstitating stem cells play their therapeutic role may be permanent rather than therapeutic.
-filled stem cells to treat the dysplate of bronchal pulmonary dysplate in children affects up to 50% of newborn health, and is the most common long-term lung disease in premature infants.
severe bronchial pulmonary dysplia is closely related to neurodevelopmental disorders, pulmonary hypertension, pulmonary heart disease, etc.
study found in an incremental dose study that gave 5-14 days of pregnancy between 5 and 14 days of pregnancy to an extremely premature baby with congested stem cell therapy.
infants treated with interstate stem cells had a lower degree of bronchulmonary dysplplitis and lower levels of inflammation than infants receiving general treatment.
The Australian team studied five babies with bronchopulmonary dysplia (at birth at 28 weeks) with intravenous retransfilm epithelluls cells at a concentration of 1 x 10 x 6 cells/kg after 36 weeks of pregnancy, with follow-up studies for 2 years.
any adverse events, growth and breathing, heart and neurodevelopmental outcomes at 6, 12, 18 and 24 months.
five babies survived at the age of two.
the mid-time time for stopping oxygen absorption was 24 months.
two of the babies had pulmonary hypertension and were in remission by the age of two.
brain MRI showed that one baby was normal and two had mild to moderate whiteness loss.
neurodegenerative diagnosis showed that one person had paraplegic cerebral palsy, three had systemic retardation and three had severe hearing loss.
no signs of tumor formation, and no long-term adverse events attributable to the drugation of endometrial epithal cells occurred. The treatment of cerebral palsy in children with interstitial stem cells between
is mainly manifested as central movement disorder and posture abnormality, and can also be accompanied by mental retardation, epilepsy, sensory impairment, language disorder and mental behavior disorder, which is one of the main diseases that cause disability of children's body movement.
are premature birth, which causes up to 15 per cent of newborns to have cerebral palsy.
a review of 47 patients found that interstate-charged stem cell therapy was the safest and most effective, both in the sac and intravenously administered.
treatment with interstate-filled stem cells, the child's symptoms, such as fever, vomiting and spasms, disappeared on their own within 72 hours.
In China, in 2017, through the project "Clinical research on the treatment of cerebral palsy in children with inter-umbilical cord-filled stem cells/neural stem cells" filed by the Health planning commission, has been officially launched, with the aim of establishing a standardized program with stem cell transplantation as the core, integrating medical treatment, nursing, rehabilitation, psychology, etc., to extend the survival time of children, improve the quality of survival of children, and reduce the burden on families and society.
the potential pathology of interstate-charged stem cells to treat autism spectrum disorders in children, such as immune system disorders, insufficient brain perfusion, and inflammation, can be used as a target for interstate stem cell therapy.
37 children with autism were treated with allogeneic adult stem cells in a clinical trial of interstate stem cells.
After 24 weeks of treatment, an assessment was conducted using measurements from the Child Autism Score Scale, the Clinical Overall Impression Scale, and the Abnormal BehaviorAlity Checklist, and found that the severity of autism symptoms in children receiving interstate stem cell therapy was significantly reduced compared to children who were not treated with interstumured stem cells.
photo source: Innovations in clinical neuroscience In June, a study published in the journal Stem Cell Translational Medicine showed that interstate-charged stem cells have good neuro-inflammatory regulation in children aged 4-9 with autism spectrum disorders Through clinical Phase I experiments, it was confirmed that 50% of children received intravenous injection of human umbilical cord tissue-filled stem cells, the core symptoms of autism spectrum disorders have been improved very well, indicating that human umbilical cord inter-filling stem cell infusion is medically well-acceptable.
children are the hope of the motherland, the future of the nation, children's health is related to the progress of society, the prosperity of the nation and the well-being of a family.
In recent years, children's health problems have attracted more and more public attention, especially the application of stem cells in children's diseases research more and more common, stem cell treatment of childhood diseases in the world has been paid much attention by scientists, I believe that with the rapid development of stem cell technology, stem cells for children's protection, will be better and better.
references: . J Immunol Res. 2015; 2015: 394917. Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease. Front Immunol. 2020; 11: 567210. Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease. Pediatr Transplant. 2017 Aug; 21(5) A Promising Future for Stem-Cell-Based Therapies in Muscular Dystrophies—In Vitro and In Vivo Treatments to Boost Cellular Engraftment. Int J Mol Sci. 2019 Nov; 20(21): 5433. Stromal derived factor-1 mediates the lung regenerative effects of mesenchymal stem cells in a rodent model of bronchopulmonary dysplasia. Respir Res. 2017; 18: 137. Malhotra, A,Lim, R,Mockler, JC,Wallace, EM. Two‐year outcomes of infants enrolled in the first‐in‐human study of amnion cells for bronchopulmonary dysplasia. STEM CELLS Transl Med.2019; 1–6. [7] Wharton's Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study. Stem Cells Int. 2019; 2019: 7402151. Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders. World J Stem Cells. 2019 Feb 26; 11(2): 55–72. JM, Dawson G, Franz L, Howard J, McLaughlin C, Kistler B, Waters-Pick B, Meadows N, Troy J, Kurtzberg J: Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl Med 2020.